Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash & Current Investments (2018 - 2025)

BioNexus Gene Lab's Cash & Current Investments history spans 8 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 8.6% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, up 8.6%, while the annual FY2024 figure was $4.4 million, 3.11% down from the prior year.
  • Cash & Current Investments for Q3 2025 was $2.9 million at BioNexus Gene Lab, down from $3.1 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $5.8 million in Q1 2024 and bottomed at $1.1 million in Q1 2025.
  • The 5-year median for Cash & Current Investments is $2.1 million (2021), against an average of $2.7 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 221.75% in 2023 before it crashed 81.29% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $2.1 million in 2021, then fell by 0.24% to $2.1 million in 2022, then skyrocketed by 113.21% to $4.5 million in 2023, then fell by 3.11% to $4.4 million in 2024, then plummeted by 33.87% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cash & Current Investments are $2.9 million (Q3 2025), $3.1 million (Q2 2025), and $1.1 million (Q1 2025).